ASCO Guidelines urges discussion of breast cancer risk reduction (VIDEO)

This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.

Multiple hormonal and non-hormonal therapies are available for treating genitourinary syndrome of menopause in breast cancer survivors, but combination therapies are the most effective.

In a recent study, women diagnosed with cancer during pregnancy and postpartum periods experienced greater rates of mortality than those diagnosed outside of pregnancy.

In a recent study, ChatGPT provided accurate and consistent answers to 22 out of 25 questions on breast cancer screening.

In a recent study, the risk of developing breast cancer was greater in women with current or recent use of progestogen-only contraceptives.

An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.